Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Nov 11 2009

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced nearly 20 presentations evaluating carfilzomib and ONX 0803 (SB 1518) in hematological cancers at the 51st American Society of Hematology (ASH) Annual Meeting December 5-8, 2009 in New Orleans, LA. Among the data presentations are four oral and seven poster presentations highlighting data from the carfilzomib development program in patients with relapsed and refractory multiple myeloma. Onyx Pharmaceuticals has previously announced its intent to acquire Proteolix Inc. Until the transaction closes, carfilzomib remains an asset of Proteolix Inc.

"The breadth of data being presented at ASH showcases our growing, diverse oncology pipeline, which we expect to fuel the future growth of Onyx, and positions the company to bring multiple, new treatment options to cancer patients," said Todd Yancey, vice president clinical development at Onyx. "Despite recent treatment advances, multiple myeloma remains a disease with poor long-term survival and there is a tremendous need for new therapies. Assuming the Proteolix transaction closes, our development plan will include evaluating carfilzomib, a next-generation selective proteasome inhibitor, across multiple lines of therapy, as a single agent and in combination with other therapies for the treatment of multiple myeloma."

Carfilzomib data highlights include:

Multiple Myeloma

• Updated Results of Bortezomib-Naive Patients in PX-171-004, an Ongoing, Open-Label, Phase II Trial of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM)
  • Dr. Michael Wang, University of Texas MD Anderson Cancer Center
  • Monday, December 7, 2009, 7:15 - 7:30 a.m., La Nouvelle Ballroom AB
  • Oral Session: Myeloma - Therapy, Excluding Transplantation I
  • Abstract # 302

• PX-171-004, an Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results from the Bortezomib-Treated Cohort
• Dr. David Siegel, Hackensack University Medical Center
• Monday, December 7, 2009, 7:30 - 7:45 a.m., La Nouvelle Ballroom AB
• Oral Session: Myeloma - Therapy, Excluding Transplantation I
• Abstract # 303

• Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM)
• Dr. Ruben Niesvizky, New York Presbyterian Hospital-Cornell Medical Center
• Monday, December 7, 2009, 7:45 - 8:00 a.m., La Nouvelle Ballroom AB
• Oral Session: Myeloma - Therapy, Excluding Transplantation I
• Abstract # 304

• Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma is Associated with Minimal Peripheral Neuropathic Effects
• Dr. Ravi Vij, Washington University School of Medicine
• Monday, December 7, 2009, 11:15 - 11:30 a.m., Hall F
• Oral Session: Myeloma -Therapy Excluding Transplantation: New Drugs in Multiple Myeloma and Amyloidosis
• Abstract # 430

ONX 0803 (SB1518) data highlights include:

Lymphoma

• Phase I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biological Activity
• Dr. Anas Younes, University of Texas MD Anderson Cancer Center
• Monday, December 7, 2009, 4:00 - 4:15 p.m., R02-R05
• Oral Session: Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: New Targets in the Treatment of Lymphomas
• Abstract # 588